Aktienanalyse zu American Shared Hospital Services (AMS)AMSAmerican Shared Hospital Services

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally. It operates in the Industrials sector (SERVICES-MEDICAL LABORATORIES industry).

American Shared Hospital Services (AMS) is currently trading at $1.28, with a low RSI of 31.235 indicating it is oversold. The company reported a significant revenue growth of 19.2% year-over-year in Q2 2026, reaching $8.4 million, which shows strong operational performance. Additionally, the stock has a forward P/E ratio of 44.64, suggesting growth potential despite current losses. The main risk is the negative net income, which was -$998,000 in Q2 2026, but the improving cash flow and revenue growth provide a solid foundation for recovery.